Varicella: to vaccinate or not to vaccinate?
Cisapride decreases prolonged episodes of reflux in infants with reflux-associated bronchopulmonary disease and reduces neonatal postoperative ileus: randomised placebo controlled trial.
Abstract
1 CSM/MCA. Current Problems in Pharmacovigilance 1998;24. 2 Bernardini S, Semama DS, Huet F, Sgro C, Gouyon JB. EVects of cisapride on QTc interval in neonates. Arch Dis Child 1997;77:F241–3. 3 Schwartz PJ, Stramba-Badiale M, Segantini A, et al. Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med 1998;338:1709–14. 4 Valdes L, Champel V, Olivier C, Jonville-Bera AP, Autret E. Syncope with long QT interval in a 39 day-old infant treated with cisapride. Arch Pediatr 1997;4:535–7. 5 CSM/MCA. Current Problems in Pharmacovigilance 1996;22. 6 Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI. Proarrhythmia associated with cisapride in children. Pediatrics 1998;101: 1053–6. 7 LupoglazoV JM, Bedu A, Faure C, et al. Long QT syndrome under cisapride in neonates and infants. Arch Pediatr 1997;4:509–14. 8 Levine A, Fogelman R, Sirota L, Zangen Z, Shamir R, Dinari G. QT interval in children and infants receiving cisapride. Pediatrics 1998;101:E9. (http://www.pediatrics.org) 9 Hedner T, Hedner J, Gelin-Friberg A, et al. Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers. Eur J Clin Pharmacol 1990;38:629–31. 10 Melis K, Janssens G. Long-term use of cisapride (Prepulsid) in premature neonates. Acta Gastroenterol Belg 1990;53:372–5. 11 Lander A, Redkar R, Nicholls G, et al. Cisapride reduces neonatal postoperative ileus: randomised placebo controlled trial. Arch Dis Child 1997;77: F119–22. 12 Vandenplas Y, Ashkenazi A, Belli D, et al. A proposition for the diagnosis and treatment of gastro-oesophageal reflux disease in children: a report from a working group on gastro-oesophageal reflux disease. Working Group of the European Society of Paediatric Gastroenterology and Nutrition (ESPGAN). Eur J Pediatr 1993;152:704–11. 13 Cucchiara S, Staiano A, Boccieri A, et al. EVects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. Gut 1990;31:21–5. 14 Vandenplas Y, de Roy C, Sacre L. Cisapride decreases prolonged episodes of reflux in infants. J Pediatr Gastroenterol Nutr 1991;12:44–7. 15 Iacono G, Carroccio A, Montalto G, et al. Evaluation of the eVectiveness of cisapride in the treatment of gastroesophageal reflux. Minerva Pediatr 1992;44:613–16. 16 Saye Z, Forget PP. EVect of cisapride on esophageal pH monitoring in children with reflux-associated bronchopulmonary disease. J Pediatr Gastroenterol Nutr 1989;8:327–32. 17 Malfroot A, Vandenplas Y, Verlinden M, Piepsz A, Dab I. Gastroesophageal reflux and unexplained chronic respiratory disease in infants and children. Pediatr Pulmonol 1987;3:208–13. 18 Saye ZN, Forget PP, Geubelle F. EVect of cisapride on gastroesophageal reflux in children with chronic bronchopulmonary disease: a double-blind cross-over pH-monitoring study. Pediatr Pulmonol 1987;3:8–12. 19 Van Eygen M, Van Ravensteyn H. EVect of cisapride on excessive regurgitation in infants. Clin Ther 1989;11:669–77. 20 Cucchiara S, Staiano A, Capozzi C, Di Lorenzo C, Boccieri A, Auricchio S. Cisapride for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1987;62:454–7. 21 Rode H, Stunden RJ, Millar AJ, Cywes S. Esophageal pH assessment of gastroesophageal reflux in 18 patients and the eVect of two prokinetic agents: cisapride and metoclopramide. J Pediatr Surg 1987;22:931–4. 22 Malfroot A, Dab I. New insights on gastro-oesophageal reflux in cystic fibrosis by longitudinal follow up. Arch Dis Child 1991;66:1339–45. 23 Dab I, Malfroot A. Gastroesophageal reflux: a primary defect in cystic fibrosis? Scand J Gastroenterol 1988;143(suppl):125–31. 24 Murray RD, Li BU, McClung HJ, Heitlinger L, Rehm D. Cisapride for intractable constipation in children: observations from an open trial. J Pediatr Gastroenterol Nutr 1990;11:503–8. 25 Nurko S, Garcia-Aranda JA, Guerrero VY, Worona LB. Treatment of intractable constipation in children: experience with cisapride. J Pediatr Gastroenterol Nutr 1996;22:38–44. 26 Staiano A, Cucchiara S, Andreotti MR, Minella R, Manzi G. EVect of cisapride on chronic idiopathic constipation in children. Dig Dis Sci 1991; 36:733–6. 27 Staiano A, Del Giudice E, Simeone D, Miele E, Marino A. Cisapride in neurologically impaired children with chronic constipation. Dig Dis Sci 1996;41:870–4. 28 Gil Vernet JM, Casasa JM, Boix Ochoa J, Salas A, Broto J, Marhuenda C. Intestinal dysmotility-pseudo-obstruction. Cir Pediatr 1992;5:87–95. 29 Hyman PE, Di Lorenzo C, McAdams L, Flores AF, Tomomasa T, Garvey TQ III. Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. Am J Gastroenterol 1993;88:832–6. 30 Di Lorenzo C, Reddy SN, Villanueva-Meyer J, Mena I, Martin S, Hyman PE. Cisapride in children with chronic intestinal pseudoobstruction. An acute, double-blind, crossover, placebo-controlled trial. Gastroenterology 1991;101:1564–70. 31 Bindl L, Buderus S, Ramirez M, KirchhoV P, Lentze MJ. Cisapride reduces postoperative gastrocaecal transit time after cardiac surgery in children. Intensive Care Med 1996;22:977–80.